Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous condition characterized by chronic airway inflammation, progressive airway obstruction, persistent respiratory symptoms, and acute exacerbations.[@CIT0001] In 2016, COPD was the third leading cause of death worldwide, and the eighth greatest cause of increased health burden as measured by disability-adjusted life years.[@CIT0002],[@CIT0003] Much of the morbidity and mortality associated with COPD are attributed to the frequency and severity of exacerbations.[@CIT0004],[@CIT0005] A combination of an inhaled corticosteroid (ICS), a long-acting β~2~-agonist (LABA), and a long-acting muscarinic receptor antagonist (LAMA), often termed triple therapy, is recommended for patients with COPD who experience exacerbations.[@CIT0001] However, some patients with COPD continue to exacerbate while receiving triple therapy and may require additional treatment.[@CIT0006],[@CIT0007]

To date, several studies have demonstrated that about two-thirds of patients with COPD have blood eosinophil levels ≥150 cells/µL or fluctuating above and below 150 cells/µL.[@CIT0008],[@CIT0009] Blood eosinophil counts may provide an indication of exacerbation risk. For example, a cross-sectional study evaluating electronic medical records and insurance claims data showed that there was a trend for higher all-cause and COPD-related healthcare costs in patients with COPD who had blood eosinophil counts ≥150 cells/µL compared with patients with blood eosinophil counts \<150 cells/µL.[@CIT0008] Similar trends were also seen in the same study when using a blood eosinophil count threshold of 300 cells/µL.[@CIT0008] Other recent studies in patients with COPD have also demonstrated that blood eosinophil counts ≥300 cells/µL are associated with an increased risk of exacerbations.[@CIT0010],[@CIT0011]

Patients with COPD who experience frequent exacerbations and who are receiving triple therapy have a clear unmet treatment need and may benefit from further targeted treatment. Several novel-targeted therapies currently in development reduce eosinophil counts in the blood and tissues by binding to interleukin-5 receptors on the eosinophil surface.[@CIT0012],[@CIT0013] Currently, the relative size of the population of patients with COPD who may be eligible for further targeted treatment is poorly understood. The objectives of this analysis were to describe the characteristics, and estimate the proportion, of patients with COPD currently prescribed triple therapy who have a history of exacerbations in the last 12 months. These patients were also characterized according to blood eosinophil count (150, 150--\<300, and ≥300 cells/µL).

Materials And Methods {#S0002}
=====================

Study Design {#S0002-S2001}
------------

This was an analysis of the Adelphi Real-World Respiratory Disease Specific Programme (DSP) database (GSK ID: HO-18-19326). The database contains 2017 DSP COPD survey results collected from patients with COPD from five European countries (France, Germany, Italy, Spain, UK) who had consulted with a primary care physician or specialist respiratory physician. The DSP is conducted annually and does not test any specific hypotheses but provides valuable information from real-world clinical practice. The DSP methodology has been described previously[@CIT0014] and is summarized in [[Supplementary Figure 1](https://www.dovepress.com/get_supplementary_file.php?f=217503.docx)]{.ul}. In brief, physicians provided information on specific patients using physician-completed record forms (PRF), and these patients provided information on themselves and their disease at the time of consultation with the physician using patient self-completion questionnaires (PSC). The 2017 DSP COPD survey was conducted between February and March 2017. For each patient, the index date was the date within this period on which the PRF and PSC were completed. Relevant data were collected on this date or from recent medical history (up to 12 months prior to index date for all objectives with the exception of blood eosinophil count, which was taken from the most recent measurement available at any time in the past); no follow-up information was collected. Data were collected by local fieldwork partners, and both physician and patient data were de-identified prior to receipt by Adelphi. The survey received ethical approval from the Freiburger Ethic-Kommission International (FEKI Code 017/1014). This analysis complied with all applicable laws regarding patient privacy.

Study Population {#S0002-S2002}
----------------

Physician criteria for inclusion in the COPD DSP were primary care physicians or respiratory specialists with a workload minimum per week of three patients with COPD. The PRF was completed by the physician for the next five consecutive patients with physician-confirmed airflow obstruction and a diagnosis of COPD to eliminate physician sampling bias. Completion of the PSC was voluntary and was therefore not completed by every patient. Patients with a physician-confirmed current co-diagnosis of asthma were excluded.

Blood eosinophil counts were reported by the physician on the index date, using the most recent available result from patient medical records. Patients were stratified by blood eosinophil count as follows: (1) none measured; (2) measured; (3) \<150 cells/μL; (4) ≥150 cells/μL; (5) 150--\<300 cells/μL; and (6) ≥300 cells/µL. The proportion of patients who experienced ≥2 moderate or ≥1 severe acute exacerbations of COPD (AECOPD) in the previous 12 months while being treated with triple therapy (defined as current prescription at index of any combination of ICS + LAMA + LABA to treat COPD) was also assessed. AECOPD events were collected by physicians using the PRF form using patient medical records from the previous 12 months. A moderate AECOPD was defined as management with oral corticosteroids and/or antibiotic and/or visit to emergency department (confirmed by a physician). A severe AECOPD was defined as a physician-confirmed hospital admission with an overnight stay. Two patient cohorts were defined based on a combination of the following criteria: ≥2 moderate or ≥1 severe AECOPD in the previous 12 months while being treated with triple therapy and a blood eosinophil count of ≥150 cells/µL (T-AECOPD-EOS150 cohort) or ≥300 cells/µL (T-AECOPD-EOS300).

Exact dates of AECOPDs and blood eosinophil measures were not captured in order to keep the data anonymized.

Objectives {#S0002-S2003}
----------

Objectives of the study were To describe the demographics and clinical characteristics of the total COPD population and the patient subgroups stratified by blood eosinophil count and exacerbation history/current therapy;To describe the proportion of patients matching a COPD patient phenotype considered eligible for further targeted therapies.

Clinical characteristics recorded included comorbidities, current COPD therapy, forced expiratory volume in 1 second (FEV~1~), Modified Medical Research Council Dyspnea Scale (mMRC) score, COPD Assessment Test (CAT) score, EuroQol 5 3-level questionnaire (EQ-5D-3L), EuroQol visual analogue scale (EQ-VAS), and healthcare resource utilization (primary care visits, specialist care visits, and inpatient days in hospital).

Statistical Analysis {#S0002-S2004}
--------------------

Raw counts and proportions were used for all data presented, with the exception of the proportion of patients in the population leading to the T-AECOPD-EOS150 and T-AECOPD-EOS300 cohorts. For these populations, a weight was applied to adjust for four areas of the DSP that could affect the probability of selection of each patient (frequency of physician visits, number of patients managed by the physician, specialty of each physician, and country) ([[Supplementary methods](https://www.dovepress.com/get_supplementary_file.php?f=217503.docx)]{.ul}). All descriptive comparisons were made overall and by country, where appropriate.

Four sensitivity analyses were performed (summarized in [[Supplementary Figure 2](https://www.dovepress.com/get_supplementary_file.php?f=217503.docx)]{.ul}). First, the characteristics of patients who completed/did not complete a PSC were compared in the total COPD population. Second, the T-AECOPD-EOS150 and T-AECOPD-EOS300 patient cohorts were limited to patients with ≥3 months triple therapy use. Third, the T-AECOPD-EOS150 and T-AECOPD-EOS300 patient cohorts were limited to patients who had an eosinophil value recorded within the 12 months prior to index date. Finally, the same patient cohorts were limited to patients with a record for ≥3 months triple therapy use and had an eosinophil value recorded within the 12 months prior to index date.

Results {#S0003}
=======

Overall COPD Population Clinical And Demographic Characteristics {#S0003-S2001}
----------------------------------------------------------------

A total of 2876 patients with COPD from five European countries (France, Germany, Italy, Spain, UK) were included in the analysis. Patient demographics and clinical characteristics are summarized overall and by country in [Table 1](#T0001){ref-type="table"}. In total, 33.2% of the patients were female and the mean age for the population was 66 years. Approximately one-third of the patients were current smokers except in Italy and Spain where approximately one-quarter were. Diabetes was the most commonly reported comorbidity, ranging from 12.7% of the patients in the UK to 22.6% of the patients in Spain. The majority of patients in all countries (93.2--99.3%) were receiving maintenance therapy for COPD. Triple therapy was the most frequently prescribed maintenance therapy in the total population (29.2%), and in France (32.5%), Spain (36.1%), and the UK (41.1%). A total of 87.2% of the population had a CAT score ≥10. COPD-related healthcare resource utilization in the year prior to index date was high across all countries, with overall means of 4.8 primary care visits, 3.4 specialist care visits, and 1.8 inpatient days per patient in the previous 12 months. Overall, 45.9% of the patients experienced at least 1 moderate and/or severe exacerbations in the year prior to index.Table 1Patient Demographics And Clinical Characteristics Overall And For Each CountryTotal Population^a^ (N=2876)France (n=565)Germany (n=587)Italy (n=580)Spain (n=583)UK (n=561)**Age (years), mean (SD)**66.2 (9.7)64.7 (10.3)62.9 (9.8)69.6 (6.6)68.1 (9.2)65.9 (10.7)**Female, %**33.229.631.539.724.940.5**BMI (kg/m^2^), mean (SD)**26.5 (4.3)26.0 (4.7)26.2 (3.9)26.5 (3.2)27.3 (4.1)26.6 (5.3)**Current smoker, %**30.638.035.124.023.232.7**Caregiver required, %**9.27.46.28.411.412.8**Current (selected) comorbidities, %** Myocardial infarction4.22.93.92.64.57.0 Congestive heart failure6.74.07.54.610.86.4 Peripheral vascular disease6.55.19.44.67.15.9 Arthritis7.32.96.97.46.413.4 Diabetes15.813.414.915.322.612.7**Currently prescribed maintenance COPD therapy** COPD maintenance therapy, %96.598.193.299.398.593.6**Maintenance class combinations**n=2776n=554n=547n=576n=574n=525 Triple therapy (any combination of ICS + LABA + LAMA), %29.232.519.617.536.141.1 ICS/LABA FDC only, %17.819.715.927.69.216.4 LAMA only, %23.113.726.535.418.121.1 LAMA/LABA FDC only, %19.315.024.513.028.714.9 LABA only, %3.87.45.91.42.61.9 Other maintenance, %6.811.77.75.05.24.6**Current usage of slow-release theophyllines (with other treatment), %**2.00.72.20.21.45.5**mMRC score**n=1527n=268n=482n=278n=295n=204 ≥2, %40.739.235.543.244.846.1**CAT score**n=1528n=267n=480n=280n=300n=201 ≥10, %87.291.078.898.988.783.6 Mean (SD)20.2 (8.3)20.2 (7.4)18.4 (9.4)24.0 (5.1)20.2 (8.1)19.3 (8.6)**EQ-5D-3L and EQ-VAS**n=1542n=273n=490n=282n=297n=200 Mean (SD)0.77 (0.25)0.67 (0.33)0.84 (0.18)0.84 (0.10)0.70 (0.30)0.74 (0.24)**COPD-related healthcare resource utilization in the year prior to index date** Number of primary care visitsn=1423n=276n=294n=283n=294n=276 Mean (SD)4.8 (3.8)6.4 (4.1)4.4 (3.3)5.1 (3.3)4.8 (4.4)3.5 (3.3) Number of specialist care visitsn=1453n=289n=293n=297n=289n=285 Mean (SD)3.4 (3.4)2.9 (1.8)4.0 (2.0)4.1 (6.2)3.1 (2.5)2.8 (2.0) Number of inpatient days in hospitaln=2876n=565n=587n=580n=583n=561 Mean (SD)1.8 (5.1)1.5 (4.7)2.6 (6.6)0.5 (2.0)2.3 (6.1)2.0 (4.7)**Number of moderate and/or severe exacerbations per person in the last 12 months** 0, %54.149.267.556.748.448.5 1, %6.06.27.24.88.43.2 ≥2, %39.944.625.438.443.248.3 Mean (SD)1.7 (2.7)1.7 (2.2)1.0 (2.0)1.5 (2.5)2.1 (3.0)2.4 (3.3) FEV~1~/FVC measured, n (%)1864 (64.8%)352 (62.3%)294 (50.1%)380 (65.5%)441 (75.6%)397 (70.8%)**% predicted post bronchodilator FEV~1~, mean (SD)**63.0 (16.0)60.5 (17.7)67.3 (15.3)63.0 (10.1)60.7 (17.9)61.3 (18.0)**Blood eosinophil count^b^ (cells/µL)**n=762n=139n=123n=23n=216n=261 ≥150 cells/µL, %73.082.776.478.375.064.0 ≥300 cells/µL, %33.638.127.652.236.629.9 Geometric mean (95% CI)257.5 (243.6, 271.4)292.5 (258.9, 326.1)267.7 (227.6, 307.8)295.9 (227.9, 363.9)269.5 (239.9, 299.2)220.8 (203.3, 238.2)[^1][^2]

Clinical And Demographic Characteristics By Blood Eosinophil Count {#S0003-S2002}
------------------------------------------------------------------

In total, 34.4% (989/2876) of patients had at least one blood eosinophil measurement reported at the time of the survey, 77.0% (762/989) of whom had an eosinophil count (i.e., a valid value) available ([Table 2](#T0002){ref-type="table"}). Of the 762 patients for whom a blood eosinophil count was available, physicians were able to state whether this was in the last 12 months (or not) for 629 patients. Of these 629 patients, 78% (490/629) had an eosinophil measurement within the 12 months prior to index date. Among patients with a blood eosinophil count available, 27% (206/762) had counts of \<150 cells/μL, 39% had counts of 150--\<300 (300/762) cells/μL, and 34% (256/762) had counts of ≥300 cells/μL. The overall geometric mean blood eosinophil count was 257.5 cells/µL. Average age, BMI, smoking status, caregiver status, and COPD healthcare resource utilization were similar across the three blood eosinophil count groups. Myocardial infarction, peripheral vascular disease, and diabetes occurred most frequently in the ≥300 cells/μL group; 7.7%, 10.5%, and 21.5%, respectively, compared with 4.4%, 7.2% and 14.7% in the 150--\<300 cells/μL group and 4.5%, 8.1%, and 16.7% in the \<150 cells/μL group. Triple therapy was the most commonly prescribed maintenance therapy across all blood eosinophil count groups (37.7--41.8%). The proportion of patients experiencing at least one moderate and/or severe exacerbation in the year prior to index was highest in the ≥300 cells/μL group (62.5%) compared with the 150--\<300 cells/μL group (54.0%) and the \<150 cells/μL group (51.5%).Table 2Demographics And Clinical Characteristics Of Patients Stratified By Blood Eosinophil CountsBlood Eosinophils Measured (N=989)Blood Eosinophils Not Measured (N=1887)Total Population (N=989^a^)EOS \<150 Cells/µL (n=206)EOS 150--\<300 Cells/µL (n=300)EOS ≥300 Cells/µL (n=256)**Age**n=981n=205n=299n=253N=1879 Years, mean (SD)66.0 (10.5)66.0 (10.2)66.0 (9.9)66.2 (11.2)66.4 (9.3)**Female, %**33.142.230.730.533.2**BMI (kg/m^2^), mean (SD)**26.5 (4.9)25.8 (5.0)26.6 (5.2)26.8 (4.8)26.5 (3.9)**Smoking status**n=977n=202n=297n=251n=1847 Current smoker, %31.730.732.728.729.9**Caregiver status**n=955n=202n=291n=248n=1822 Caregiver required, %14.216.313.115.76.6**Current (selected) comorbidities**n=963n=198n=293n=247n=1840 Myocardial infarction, %5.64.54.47.73.4 Congestive heart failure, %8.611.18.96.55.7 Peripheral vascular disease, %8.48.17.210.55.4 Arthritis, %7.98.68.99.77.1 Diabetes, %16.916.714.721.515.3**Current prescribed maintenance COPD therapy** COPD maintenance therapy, %97.496.698.096.596.1**Maintenance class combinations**n=963n=206n=294n=247n=1813 Triple therapy (any combination of ICS + LABA + LAMA), %38.140.241.837.724.5 ICS/LABA FDC only, %12.411.111.913.420.7 LAMA only, %18.218.617.016.225.6 LAMA/LABA FDC only, %22.023.120.123.917.8 LABA only, %2.11.51.71.24.7 Other maintenance, %7.35.57.57.76.6**Current usage of slow-release theophyllines (with other treatment), %**3.86.34.03.91.0**mMRC score**n=503n=97n=169n=128n=1024 ≥2, %41.648.539.135.940.3**CAT score**n=505n=97n=170n=130n=1023 ≥10, %89.986.688.290.885.8 Mean (SD)20.8 (8.0)21.0 (8.8)19.7 (8.0)20.9 (7.5)19.9 (8.4)**EQ-5D-3L and EQ-VAS**n=504n=96n=170n=131n=1038 Mean (SD)0.71 (0.29)0.71 (0.30)0.75 (0.26)0.65 (0.33)0.80 (0.22)**COPD-related healthcare resource utilization in the year prior to index date** Number of primary care visitsn=473n=75n=108n=162n=950 Mean (SD)5.9 (4.8)5.2 (5.6)5.5 (4.3)6.0 (4.8)4.3 (3.1) Number of specialist care visitsn=516n=131n=192n=94n=937 Mean (SD)3.5 (2.5)3.5 (2.8)3.4 (2.2)3.6 (3.0)3.3 (3.8) Number of inpatient days in hospitaln=989n=206n=300n=256n=1887 Mean (SD)2.6 (6.5)3.4 (7.4)2.2 (5.4)2.8 (6.8)1.2 (3.8)**Number of moderate and/or severe exacerbations per person in the last 12 months** 0, %44.448.546.037.559.2 1, %5.84.45.36.66.1 ≥2, %49.847.148.755.934.7 Mean (SD)2.4 (3.2)2.4 (3.6)2.1 (2.6)2.7 (3.3)1.4 (2.3)**% predicted post bronchodilator FEV~1~, mean (SD)**58.7 (17.2)55.4 (18.1)59.1 (17.0)60.2 (16.0)65.2 (14.8)**Most recent record of blood eosinophil count (cells/uL)**n=762n=206n=300n=256n=0 Geometric mean (95% CI)257.5 (243.6, 271.4)90.9 (86.2, 95.6)200.2 (196.9, 203.6)458.7 (432.7, 484.8)N/A[^3][^4]

Clinical And Demographic Characteristics Among Triple Therapy Users With A History Of Exacerbations {#S0003-S2003}
---------------------------------------------------------------------------------------------------

Of the 811 patients receiving triple therapy, 546 (67.3%) experienced ≥2 moderate or ≥1 severe AECOPD within the 12 months prior to index date ([Table 3](#T0003){ref-type="table"}). Compared with the rest of the COPD population, these patients had higher incidences of all selected comorbidities, greater use of slow-release theophyllines, higher mMRC and CAT scores, lower EQ-5D scores, indicating worse health-related quality of life (HRQoL), poorer lung function, as shown by lower percent predicted FEV~1~, and greater use of healthcare resources (primary care visits, specialist care visits, and inpatient days).Table 3Demographics And Clinical Characteristics Of Patients With COPD By Exacerbations History/Current TherapyPatients With COPD With ≥ 2 Moderate or ≥ 1 Severe AECOPD Within The Last 12 Months And Currently Being Treated With Triple Therapy (n=546)Total COPD Population (n=2330)**Age**n=540n=2320 Years, mean (SD)68.7 (9.4)65.7 (9.7)**Female, %**29.134.1**BMI (kg/m^2^), mean (SD)**n=507 26.9 (4.8)n=2240 26.4 (4.1)**Smoking status**n=536n=2228 Current smoker, %29.330.9**Caregiver status**n=534n=2243 Caregiver required, %19.56.8**Current (selected) comorbidities**n=540n=2263 Myocardial infarction, %6.73.6 Congestive heart failure, %13.95.0 Peripheral vascular disease, %9.35.8 Arthritis, %7.27.4 Diabetes, %22.014.4**Current prescribed treatment** COPD maintenance therapy, %10095.7**Maintenance class combinations**n=546n=2230 Triple therapy (any combination of ICS + LABA + LAMA), %10011.9 ICS/LABA FDC only, %022.2 LAMA only, %028.7 LAMA/LABA FDC only, %024.0 LABA only, %04.8 Other maintenance, %08.5**Current usage of slow-release theophyllines (with other treatment), %**6.21.0**mMRC score**n=256n=1271 ≥2, %69.135.0**CAT score**n=263n=1265 ≥10, %95.485.5 Mean (SD)24.9 (7.3)19.2 (8.1)**EQ-5D-3L and EQ-VAS**n=260n=1282 Mean (SD)0.63 (0.32)0.80 (0.22)**COPD-related healthcare resource utilization in the year prior to index date** Number of primary care visitsn=223n=1200 Mean (SD)6.3 (4.5)4.6 (3.6) Number of specialist care visitsn=323n=1130 Mean (SD)3.8 (2.3)3.2 (3.7) Number of inpatient days in hospitaln=546n=2330 Mean (SD)3.1 (7.2)0.9 (2.9)**% predicted post bronchodilator FEV~1~, mean (SD)**n=276 53.5 (16.3)n=1038 65.6 (14.9)**Most recent record of blood eosinophil count (cells/uL)**n=209n=553 ≥150 cells/µL, %73.772.7 ≥300 cells/µL, %33.533.6 Geometric mean (95% CI)243.6 (221.4, 265.9)262.8 (245.6, 280.0)[^5]

T-AECOPD-EOS150 And T-AECOPD-EOS300 Cohorts {#S0003-S2004}
-------------------------------------------

Overall, 10.6% of the patients met the triple therapy and AECOPD criteria and had a blood eosinophil count of ≥150 cells/μL (T-AECOPD-EOS150 cohort); and 6.2% of the patients met the triple therapy and AECOPD criteria and had a blood eosinophil count of ≥300 cells/µL (T-AECOPD-EOS300 cohort). The weighted percentages of all patients with COPD who were prescribed triple therapy, had ≥2 moderate or ≥1 severe AECOPD, and a blood eosinophil count ≥150 or ≥300 cells/µL are shown in [Figure 1](#F0001){ref-type="fig"} and presented by country in [[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=217503.docx)]{.ul}.Figure 1Proportion of patients from the total diagnosed COPD sample (weighted absolute percentages) who were prescribed triple therapy, had ≥2 moderate or ≥1 severe AECOPD, and had a blood eosinophil count ≥150 cells/µL and ≥300 cells/µL in the five European countries studied.**Notes:** ^a^Weighted using an adjustment factor to account for physician consultation rates, and consultation workload, physician specialty, and country size; ^b^France, Germany, Italy, Spain, and UK; ^c^Based on the total with eosinophil count collected as part of routine clinical care (n=762).**Abbreviations:** AECOPD, acute exacerbations of COPD; COPD, chronic obstructive pulmonary disease; EOS, blood eosinophil count.

Sensitivity Analyses {#S0003-S2005}
--------------------

The sensitivity analysis of the characteristics for patients who completed a PSC (n=1563) compared with those that did not complete the PSC (n=1313) showed that the two populations were similar in terms of age, BMI, smoking status, and currently prescribed treatment (data not shown). In addition, further sensitivity analyses indicated that the weighted proportions of patients eligible for inclusion in the T-AECOPD-EOS150 and T-AECOPD-EOS300 cohorts were similar to the main analysis when the populations were limited to those treated with triple therapy for ≥3 months (9.1% and 5.8%, respectively, compared with 10.6% and 6.2% for the main analysis) and to those whose blood eosinophil count had been measured within the 12 months prior to index date (11.1% and 6.1%, respectively).

Discussion {#S0004}
==========

In this analysis of survey data from 2876 patients with COPD in Europe, between 17.5% (Italy) and 41.1% (UK) of patients were currently prescribed triple therapy, reflecting country-specific differences in physician prescribing habits. Over half of patients currently prescribed triple therapy had ≥1 severe or ≥2 moderate AECOPDs in the last 12 months; 10.6% and 6.2% of the COPD population also had blood eosinophil counts ≥150 cells/µL and ≥300 cells/µL, respectively. These data suggest patients with COPD who display these characteristics may benefit from eosinophil-targeted therapies.

COPD-related healthcare resource utilization in the year prior to index date was high across all countries, with overall means of 4.8 primary care visits, 3.4 specialist care visits, and 1.8 inpatient days per patient. These figures are similar to those reported in other studies.[@CIT0015],[@CIT0016] For example, the rate of 4.8 primary care visits per patient in the 12 months prior to index shown in the current analysis was comparable to the mean of 3.6 primary care visits within a 12-month period shown by Ding et al,[@CIT0016] which is based on a previous Adelphi DSP survey conducted in 2013. It is worth noting that patients enrolled in the Adelphi DSP annual survey are different each year; therefore, it is unlikely that those who participated in the 2013 survey also took part in the 2017 survey. In addition, a COPD cohort study using electronic medical records identified from the Clinical Practice Research Datalink (CPRD) reported an overall mean value of 12.3 GP practice medical visits over 12 months in the UK. However, it is likely that this figure is higher than that seen in our study because it includes all-cause GP consultations, not those exclusively due to COPD.[@CIT0015]

The current analysis also determined demographic and clinical characteristics in patients stratified by the presence/absence of a blood eosinophil count measurement, and further by blood eosinophil count, where available. Blood and sputum eosinophil counts have been shown to be associated with disease burden in patients with COPD and may act as a surrogate biomarker to predict clinical outcomes.[@CIT0008],[@CIT0011],[@CIT0017]--[@CIT0019] The measurement of blood eosinophil counts is practical and the collection of blood samples is much simpler than collecting sputum samples, which requires specialist training.[@CIT0020] However, the measurement of blood eosinophil counts in patients with COPD is only now becoming more established in clinical practice. This is demonstrated by the fact that only 34.4% of the patients in the current analysis had a blood eosinophil measurement recorded in the patient record form, although it is important to note that this is an increase from 26.0% of the patients who had an eosinophil measurement available in the 2016 Adelphi Respiratory DSP (data not published). In general, the group of patients with a blood eosinophil count measurement available tended to present with a severe exacerbation history and multiple comorbidities. This may indicate that there is a greater likelihood of blood eosinophil count being measured if a patient has multiple morbidities.

Of those patients who did have an eosinophil count available, 27% had counts of \<150 cells/μL, 39% had measurements of 150--\<300 cells/μL, and 34% had eosinophil counts ≥300 cells/μL. Our analysis supported previous findings demonstrating higher symptom burden in terms of exacerbations experienced in the 12 months prior to index date in patients with eosinophil counts ≥300 cells/μL compared with those in the two lower eosinophil count groups.[@CIT0008] Our analysis also demonstrated that the ≥300 cells/μL eosinophil group had the lowest reported HRQoL. Within the COPD population, both blood eosinophil counts of ≥150 cells/μL and higher rates of exacerbations have been associated with significantly higher all-cause and COPD-related healthcare costs,[@CIT0008] while COPD-specific mortality and COPD exacerbations have been linked to higher eosinophil counts.[@CIT0005],[@CIT0011],[@CIT0017],[@CIT0019] Indeed, our own analysis highlighted more severe disease in terms of comorbidities, mMRC and CAT scores, and use of healthcare resources, in patients who experienced ≥2 moderate or ≥1 severe AECOPD in the 12 months prior to index date, compared with patients who did not experience this frequency of exacerbations in the same period. Together, these results demonstrate a higher clinical disease burden in patients with higher blood eosinophil counts and/or frequent COPD exacerbations (≥2 moderate or ≥1 severe AECOPD).

The guidance for patients with COPD who continue to experience exacerbations is to prescribe inhaled triple therapy in an attempt to control these episodic deteriorations of COPD.[@CIT0001] However, our analysis found that a small proportion (10.6%) of the COPD population continued to experience exacerbations while receiving triple therapy and also had blood eosinophil counts ≥150 cells/μL (T-AECOPD-EOS150 cohort), which is consistent with findings from another study.[@CIT0021] These figures were also similar in sensitivity analyses that selected patients who had ≥3 months of triple therapy, and in patients who had a blood eosinophil count measurement within 12 months of the index date. These results highlight the need for targeted novel treatment strategies for patients with COPD.

The current analysis has several limitations. First, patients participating in the DSP survey may not reflect the general COPD population, as those who have more severe disease are likely to have more frequent physician visits and may be more likely to be sampled than those who do not consult their physician as often. Second, the real-world nature of the DSP means that data are collected as part of routine clinical practice. As a result, the diagnosis of COPD may not have involved the use of spirometry, which is recommended as the gold standard for COPD diagnosis,[@CIT0001] as spirometry values may not necessarily have been known to the physician completing the patient record form.

Conclusion {#S0005}
==========

This analysis indicates that it is possible to define a subpopulation of patients with high disease burden who continue to experience exacerbations despite receiving triple therapy during routine clinical practice and that these patients may benefit from eosinophil-targeted therapies. Further research concerning the role of eosinophilic inflammation in COPD patients and treatment response, in addition to characterization of this patient population, may also help aid clinical decision-making.
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Ethics Approval And Informed Consent {#S0007}
====================================

The Adelphi survey received ethical approval from the Freiburger Ethic-Kommission International (FEKI Code 017/1014). This analysis complied with all applicable laws regarding patient privacy.

Data Availability {#S0008}
=================
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[^1]: **Notes:** ^a^Total population from France, Germany, Italy, Spain, and UK; ^b^Most recent measurement recorded.

[^2]: **Abbreviations:** BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimension 3-level questionnaire; EQ-VAS, visual analogue scale; FDC, fixed-dose combination; FEV~1~, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic receptor antagonist; mMRC, Modified Medical Research Council Dyspnea Scale; SD, standard deviation.

[^3]: **Notes:** ^a^Of 989 patients who had a blood eosinophil count measured, 762 had a value and 227 were measured but had no value recorded.

[^4]: **Abbreviations:** BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimension 3-level questionnaire; EQ-VAS, visual analogue scale; FDC, fixed-dose combination; FEV~1~, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic receptor antagonist; mMRC, Modified Medical Research Council Dyspnea Scale; SD, standard deviation.

[^5]: **Abbreviations:** BMI, body mass index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimension 3-level questionnaire; EQ-VAS, visual analogue scale; FDC, fixed-dose combination; FEV~1~, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic receptor antagonist; mMRC, Modified Medical Research Council Dyspnea Scale; SD, standard deviation.
